Centene reported a fourth quarter 2025 adjusted diluted loss per share of $1.19, resulting in full-year adjusted EPS of $2.08 on revenue of $174.6 billion. Despite describing 2025 as 'undeniably challenging,' management raised 2026 guidance to adjusted EPS greater than $3.00, representing over 40% year-over-year growth. This turnaround is driven by Medicaid margin stabilization (Q4 HBR improved to 93%), significant recovery in the Marketplace business (targeting ~4% pretax margin), and continued progress toward Medicare Advantage breakeven. Key strategic initiatives include aggressive fraud detection in ABA therapy, litigation against No Surprises Act abuse, and AI-driven cost containment.
| Metric | Value | Change |
|---|---|---|
| Q4 2025 Adjusted EPS | -$1.19 | Loss per share |
| FY 2025 Adjusted EPS | $2.08 | Full year results |
| FY 2025 Revenue | $174.6 billion | Premium and service revenue |
| FY 2026 Guidance EPS | >$3.00 | >40% year-over-year growth |
| Q4 2025 Medicaid HBR | 93.0% | Improved 40 bps sequentially, 190 bps from Q2 |
| FY 2026 Guidance HBR | 90.9% - 91.7% | Midpoint down 60 bps from 2025 |
| FY 2025 SG&A Expense Ratio | 7.4% | Down 110 bps from 2024 |
Medicaid Operational Turnaround: Centene is aggressively attacking cost drivers, specifically Applied Behavioral Analysis (ABA) therapy, where they identified 'outlier providers' billing excessive hours. This data-driven approach, combined with rate advocacy (5.5% composite increase in 2025) and network optimization, drove a 190 bps HBR improvement from Q2 to Q4 (93% in Q4). Management expects flat HBR in 2026 despite mid-4s trend, implying further operational leverage.
Marketplace Pricing Discipline: Following a -1% pretax margin in 2025, Centene implemented 'mid-30s percent' rate increases for 2026 to account for the expiration of enhanced premium tax credits (EAPTC) and medical trend. They are navigating a shift in product mix toward Bronze plans (30%+ of enrollment) and are taking a 'litigious posture' against No Surprises Act (NSA) abuse to protect margins.
Medicare Advantage Restructuring: The company is intentionally shrinking its MA footprint to refine its value proposition, expecting Q1 membership decline. The goal remains breakeven in 2027. However, the 2027 advance notice suggests rate pressure, requiring continued efficiency (SG&A down 110 bps in 2025) and focus on dual-eligible populations.
Part D as a Growth Engine: The Medicare segment is growing revenue by ~$7.5 billion in 2026, driven primarily by the PDP business. Despite Inflation Reduction Act (IRA) headwinds, Centene is growing membership (8.1M to 8.7M) and leveraging yield increases to maintain a ~2% pretax margin target.
AI and Data Integration: Management highlighted the use of '75 algorithms' to triangulate fraud and the integration of 'AgenTek' capabilities to automate operations. This technological focus is a key lever for reducing SG&A and improving payment integrity, supporting the long-term margin expansion thesis.
Medicaid Trend Stickiness: While HBR improved, underlying trend remains elevated at 'mid-fours' for 2026 (down from mid-sixes in 2025). Drivers like behavioral health, home health, and high-cost drugs persist. Management's guidance assumes 'flat HBR,' which requires flawless execution on cost containment; any slippage could derail the earnings recovery.
Marketplace Membership & Mix Volatility: The shift to Bronze plans (historically more volatile) and the drop in paid membership to 3.5M (from 5M in Dec) introduces uncertainty. Management admits 'paid rates are below historical levels,' relying on pricing adequacy to compensate for a potentially less healthy risk pool post-EAPTC expiration.
Regulatory & Litigation Risks: The 'weaponized' No Surprises Act (NSA) is forcing Centene into costly litigation and accruals. Additionally, the 2027 Medicare advance notice indicates rates will be 'more pressured' than expected, potentially threatening the 2027 MA breakeven goal.
Cash Flow Constraints: The company ended 2025 with only ~$400M of cash available. While debt reduction is a priority ($189M paid in Q4), the limited liquidity restricts flexibility for aggressive share buybacks (none in guidance) or M&A, making operational execution critical.
Overall: Management displayed a tone of resilient confidence and disciplined execution. Sarah London was assertive and 'fired up,' acknowledging past difficulties but emphasizing the 'powerful engine' of the Centene team. Drew Asher provided a prudent, numbers-focused perspective, repeatedly characterizing assumptions as 'prudent' to manage expectations.
Confidence: HIGH - Management provided specific guidance ranges and detailed operational levers (e.g., ABA fraud reduction, network optimization) to support their >40% growth target. They were direct in addressing analyst skepticism regarding Medicaid rates, citing 'proof points' of success.
Greater than $3.00, representing more than 40% year-over-year growth. This outlook assumes Medicaid margin stability, significant margin recovery in Marketplace, and continued progress toward Medicare Advantage breakeven.
$170 billion to $174 billion. Driven by growth in the Medicare PDP segment (~$7.5B increase), partially offset by lower revenue in Medicaid and Marketplace due to membership declines and rate changes.
90.9% to 91.7%. Assumes a flat Medicaid HBR year-over-year at 93.7%, improvement in Marketplace, and a higher PDP HBR due to the Inflation Reduction Act (IRA) direct subsidy changes.
Medicaid member months expected to be down 5-6%. Marketplace membership expected to end Q1 at roughly 3.5 million. Medicare total membership expected to grow to approximately 8.7 million.
Hedging & Uncertainty: Management frequently used the word 'prudent' to characterize their guidance and assumptions, a classic hedge to lower expectations. Phrases like 'we expect,' 'we anticipate,' and 'at this time' were used to qualify forward-looking statements. However, they reduced hedging when discussing specific operational wins (e.g., ABA fraud), showing higher confidence in execution than macro forecasts.
While 2025 was undeniably challenging, disciplined execution enabled us to close the year slightly ahead of the expectations. - Sarah London, CEO
We have prudently positioned our 2026 outlook incorporating an expectation that policy-related variability will continue. - Sarah London, CEO
If that is all we deliver, I will be very disappointed. - Sarah London, CEO
The No Surprises Act... has increasingly become weaponized by market participants. - Sarah London, CEO
We are starting with a prudent assumption around that 4.5% for 2026. - Sarah London, CEO
Analyst Sentiment: Analysts were skeptical regarding the sustainability of Medicaid margins given the rate/trend disconnect (Ann Hynes, Jessica Lake). There was significant focus on the mechanics of the Marketplace shift to Bronze plans (Kevin Fischbeck) and the impact of the PBM contract renegotiation (AJ Rice).
Management Responses: Management was well-prepared and direct. Sarah London pushed back on skepticism by emphasizing 'prudent' assumptions and 'proof points' of rate corrections (e.g., Florida). Drew Asher provided detailed mathematical explanations for PDP margins and HBR mechanics. They did not deflect but rather used data to support their narrative.
Medicaid Rate Adequacy: Analysts questioned how 4.5% rate increases cover mid-4s trend. Management emphasized 'net trend' (lower than gross) and non-rate actions (program reforms).
Marketplace Bronze Shift: Concerns about the profitability of the influx of Bronze members. Management assured that pricing accounted for this mix shift and that demographics (age/gender) remain stable.
PBM Renegotiation: Analysts asked if Centene benefited from the PBM contract reset. Management confirmed their 'bespoke' contract captures all economic benefits, aiding cost structure.
Medicare Advantage Breakeven: Analysts probed the 2027 target. Management confirmed they are on track despite rate pressure, focusing on footprint refinement.
Centene presents a compelling turnaround opportunity driven by operational discipline and a low valuation base. After a 'reset' year in 2025, management has established clear visibility into 2026, guiding for >40% EPS growth to >$3.00. The primary catalysts are: (1) Medicaid margin stabilization via aggressive fraud reduction (ABA) and rate advocacy; (2) Marketplace recovery fueled by 30%+ price hikes and a shift to Bronze plans; and (3) Medicare Advantage restructuring toward a profitable 2027. Key risks include persistent Medicaid trend and regulatory headwinds (NSA, Medicare rates), but management's confident tone and detailed execution plan suggest the worst is behind them. The 'Greater than $3' guidance appears conservative, setting the stage for potential upside surprises as operational levers (AI, payment integrity) gain traction.
The No Surprises Act (NSA) is being exploited by providers through the Independent Dispute Resolution (IDR) process, creating systemic cost inflation. Centene noted it has become 'weaponized by market participants looking to extract profits,' forcing insurers to adopt a 'litigious posture' and file lawsuits to protect margins.
The expiration of enhanced premium tax credits (EAPTC) is driving a structural shift in the individual market toward lower-cost Bronze plans. Centene reported Bronze membership rising to >30% in 2026 from a historical range of 19-24%, indicating increased price sensitivity among consumers.
The Medicaid industry is facing a 'new normal' of elevated trend driven by behavioral health and post-pandemic acuity. Centene's experience of 'mid-sixes' trend in 2025, only moderating to 'mid-fours' in 2026, suggests a persistent headwind that requires data-driven cost management rather than just rate increases.